Navigation Links
Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA

LIVINGSTON, N.J. and PARSIPPANY, N.J., Nov. 10, 2011 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX), and Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the Advisory Committee for Reproductive Health Drugs of the U.S. Food and Drug Administration (FDA) is scheduled to review Columbia's New Drug Application (NDA) for progesterone vaginal gel for the reduction of risk of preterm birth in women with short uterine cervical length regardless of other risk factors in the mid-trimester of pregnancy on January 20, 2012.  

The Advisory Committee for Reproductive Health Drugs is an independent panel of experts that evaluates data concerning the efficacy and safety of marketed and investigational products for use in the treatment of reproductive conditions and makes non-binding recommendations to the FDA.  While the FDA will consider recommendations of the committee, the final decision regarding the approval of the product rests solely with the FDA.

The companies announced on June 27, 2011 that the FDA accepted the NDA for filing.  The FDA's goal is to review and act on the NDA by February 26, 2012 under the Prescription Drug User Fee Act IIII (PDUFA).  The NDA includes data from two Phase III clinical trials evaluating the use of progesterone vaginal gel in reducing the risk of preterm birth in women, as well as supportive pharmacokinetic studies.

The FDA will publish materials pertaining to the meeting at

Changes to the Advisory Committee meetings calendars may also be found on the FDA website at

About Watson PharmaceuticalsWatson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets. For press release and other company information, visit Watson Pharmaceuticals' Web site at

About Columbia LaboratoriesColumbia Laboratories, Inc. is developing products that utilize its novel bioadhesive drug delivery technologies to optimize drug delivery in a controlled, sustained manner. The Company has developed and sold six products for the U.S. market including CRINONE® (progesterone gel), for which Columbia receives royalties on annual net sales from Watson Pharmaceuticals.  CRINONE is commercialized outside the U.S. by Merck Serono. Columbia's press releases and other company information are available online at

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are indicated by the words "may," "will," "plans," "intends," "believes," "expects," "anticipates," "potential," "could," "would," "should," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the following: the outcome of further analyses by the FDA of the clinical data in the Preterm Birth NDA; success in obtaining timely approval of the Preterm Birth NDA by the FDA; the timing and level of success of a future product launch, if any; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; changes in the laws and regulations, including Medicaid; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; the ability to obtain and enforce patents and other intellectual property rights; the impact of competitive products and pricing; the timely and successful negotiation of partnerships or other transactions; the strength of the United States dollar relative to international currencies; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's and Watson's reports filed with the SEC, including, but not limited to, their respective Annual Reports on Form 10-K for the year ended December 31, 2010. Neither Columbia nor Watson undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.

CRINONE® is a registered trademark of Watson Pharmaceuticals, Inc.

(Logo: Columbia Laboratories, Inc.

For Watson Pharmaceuticals, Inc. Investors

InvestorsLawrence A. Gyenes

Patty EisenhaurSVP, Chief Financial Officer & Treasurer

VP, Investor Relations and Corp. Comm. Columbia Laboratories, Inc.

(862) 261-8141(973) 486-8860--or--

MediaSeth Lewis

Charlie MayrVP, The Trout Group LLC

SVP, Corporate Affairs(646) 378-2952

(862) 261-8483MediaAmy RaskopfPresident, Raskopf Communications, LLC(917) 673-5775

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Columbia Laboratories NDA for PROCHIEVE® Vaginal Progesterone Gel Accepted for Filing by FDA
2. Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
3. Sanofi-aventis Enters Into Research Collaboration With Columbia University to Develop New Diabetes Treatments
4. Columbia Laboratories to Discuss Fourth Quarter and Year End 2010 Financial Results on March 10, 2011, Conference Call
5. Columbia University Students Learn About Pharmacy Benefit Management From Prime Therapeutics President and CEO
6. Partners with Columbia Medical Associates to Bring Affordable Healthcare to Washington State
7. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
8. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
9. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
10. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
11. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
Post Your Comments:
(Date:11/25/2015)... issue of United States patent No. 9,192,509  entitled: " Methods and Apparatus ... AVACEN 100 dry heat therapy medical device and specific methods of use, referred to by the ... - ... ... ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
(Date:11/25/2015)... November 25, 2015 --> ... sie eine Lizenz für das Patent über eine neue ... und ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... ins Leben gerufenen und von Edelris gemeinsam mit seinen ... ein Behandlungsziel für HBV identifiziert, und es wurden neue ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 25, 2015 , ... ... Their Care Plan software creates an agreement between the practice owner and ... including financial, scheduling, monitoring, notification, and projections. Click here to ...
(Date:11/24/2015)... ... November 24, 2015 , ... Charitable giving is at its peak during ... the last five weeks of the year totalling over $358 billion in 2014. ... the nation’s charities with those individuals who want to “give back” during the holidays. ...
(Date:11/24/2015)... ... 2015 , ... The hospitals and health systems on this ... care. They have received recognition for excellence from various reputable organizations in areas ... Hospital Review selected hospitals for inclusion based on national rankings and awards from ...
(Date:11/24/2015)... ... 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus Medical ... the United States grew 400 percent between 1999 and 2010, far more than the ... percent of all fatal drug overdoses. (1) , While oxycodone and the extended release ...
(Date:11/24/2015)... ... , ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse located ... the staff members at their recovery center. The videos highlight some of the various ... the things that make their recovery program so unique. , “Making the decision to ...
Breaking Medicine News(10 mins):